Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

Transplant International

Volumn 24, Issue 12, 2011, Pages 1216-1230

  Pengel, Liset H M ^a   Liu, Liang Q ^a   Morris, Peter J ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

lymphoceles; mTOR inhibitors; randomized controlled trials; solid organ transplantation; systematic review; wound complications

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; BILIARY TRACT DISEASE; CARDIAC GRAFT REJECTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; INCISIONAL HERNIA; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCELE; MORBIDITY; ORGAN TRANSPLANTATION; PANCREAS GRAFT REJECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WOUND COMPLICATION;

ADRENAL CORTEX HORMONES; CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCELE; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 80755144030     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01357.x     Document Type: Article

References (60)

1. Russel NKI, Knight SR, Morris PJ,. Cyclosporine. In:, Morris PJ, Knechtle SJ, eds. Kidney Transplantation: Principles and Practice, 6th edn. Philadelphia: Saunders Elsevier, 2008: 234-258.
2. Langer RM, Kahan BD,. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804.
3. Stallone G, Infante B, Grandaliano G, Gesualdo L,. Management of side effects of sirolimus therapy. Transplantation 2009; 87: S23.
4. Flechner SM,. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87: S1.
5. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW,. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993; 154: 7.
6. King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI,. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75: 1437.
7. Webster AC, Lee VW, Chapman JR, Craig JC,. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006; 2: CD004290.
8. Rogers CC, Hanaway M, Alloway RR, et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc 2005; 37: 795.
9. Sandrini S, Setti G, Bossini N, et al. Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy. Clin Transpl 2009; 23: 16.
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1.
11. Pengel LH, Barcena L, Morris PJ,. The quality of reporting of randomized controlled trials in solid organ transplantation. Transpl Int 2009; 22: 377.
12. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons Ltd, 2008.
13. van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L,. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 1934.
14. Anil Kumar MS, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005; 80: 807.
15. Anil Kumar MS, Saeed MI, Ranganna K, et al. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: 5-year outcomes. Transpl Immunol 2008; 20: 32.
16. Barsoum RS, Morsey AA, Iskander IR, et al. The Cairo Kidney Center Protocol for Rapamycin-based Sequential Immunosuppression in Kidney Transplant Recipients: 2-Year Outcomes. Exp Clin Transpl 2007; 5: 649.
17. Buchler M, Caillard S, Barbier S, et al. Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin, Mycophenolate Mofetil and a 6-Month Course of Steroids. Am J Transplant 2007; 7: 2522.
18. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252.
19. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555.
20. Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008; 85: 486.
21. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
22. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
23. Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M,. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 2010; 55: 335.
24. Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin Induction and Sirolimus Versus Tacrolimus in Kidney Transplant Recipients Receiving Mycophenolate Mofetil and Steroids. Transplantation 2010; 89: 1511.
25. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036.
26. Guba M, Pratschke J, Hugo C, et al. Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: 1-Year Analysis of a Randomized Multicenter Trial. Transplantation 2010; 90: 175.
27. Kahan BD,. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194.
28. Kahan BD,. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003; 35: 37S.
29. Kahan BD, Camardo JS,. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181.
30. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J,. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68: 1526.
31. Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - an interim analysis. Am J Transplant 2005; 5: 1529.
32. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
33. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
34. MacDonald AS, Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271.
35. Machado PG, Felipe CR, Hanzawa NM, et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Clin Transpl 2004; 18: 28.
36. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, et al. Living Related Kidney Transplantation Without Calcineurin Inhibitors: initial Experience in a Mexican Center. Transplantation 2006; 82: 1533.
37. Pescovitz MD, Vincenti F, Hart M, et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol 2007; 64: 758.
38. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin Transpl 2008; 22: 141.
39. Tedesco Silva H, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401.
40. Van Gurp E, Bustamante J, Franco A, et al. Comparable renal function at 6 months with tacrolimus combined with fixed-dose sirolimus or mmf: results of a randomized multicenter trial in renal transplantation. J Transplant 2010; Epub 2010 Oct 5.
41. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
42. Vitko S, Wlodarczyk Z, Kyllonen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 2006; 6: 531.
43. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11: 66.
44. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
45. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694.
46. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377.
47. Lehmkuhl HB, Arizon J, Vigano M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88: 115.
48. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 2252.
49. Girman P, Lipar K, Koznarova R, et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. Transplant Proc 2010; 42: 1999.
50. Montagnino G, Sandrini S, Iorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008; 23: 707.
51. Sandrini S, Setti G, Bossini N, et al. Early (fifth day) vs. late (sixth month) steroid withdrawal in renal transplant recipients treated with Neoral((R)) plus Rapamune((R)): 4-yr results of a randomized monocenter study. Clin Transpl 2010; 24: 669.
52. Albano L, Berthoux F, Moal M, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88: 69.
53. Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23: 1084.
54. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
55. Pankewycz O, Said M, Feng L, et al. Conversion to Low Dose Tacrolimus or Rapamycin 3 Months After Kidney Transplant: A Prospective, Protocol Biopsy Guided Study. Vancouver, Canada: XXIII International Congress of The Transplantation Society, August 15-19, 2010.
56. Medina-Pestana J, Garcia V, David-Neto E, et al. Conversion From Tacrolimus to Sirolimus-Based Immunosuppressive Regimen in Kidney Transplant Recipients. Preliminary Results. Vancouver, Canada: XXIII International Congress of The Transplantation Society, August 15-19 2010, 2010.
57. Morris PJ, Knechtle SJ,. Kindney Transplantation: Principles and Practice, 6th edn. Philadelphia: Saunders Elsevier, 2008.
58. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transpl 2007; 21: 460.
59. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76: 1729.
60. Tiong HY, Flechner SM, Zhou L, et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation 2009; 87: 296.